Advances in Cancer Immunotherapy
A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".
Deadline for manuscript submissions: closed (20 January 2022) | Viewed by 1814
Special Issue Editor
Interests: clinical pharmacology; surgical oncology; immune-oncology; drug targeting; drug safety; breast cancer; endocrine cancer; colorectal cancer; familial cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer immunotherapy has become a powerful new approach to cancer therapy. Immunotherapy drugs have already been approved by the FDA for the treatment of multiple types of cancers, thus enhancing research interest in the field of cancer immunotherapy. Progress in cancer immunotherapy has largely been facilitated by relevant technological progress. New technologies such as next-generation sequencing have enhanced our ability to search for new targets in immuno-oncology. On the other hand, drug delivery systems such as nanoparticles and the use of T cells for drug delivery have enabled an increase in potency and the reduction of adverse events associated with cancer immunotherapy. This Special Issue is devoted to advanced technologies that lead to the implementation of cancer immunotherapy.
Dr. Eugenia Yiannakopoulou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer immunotherapy
- next-generation sequencing
- drug delivery technologies
- nanoparticles
- modulation of the immune system
